Parmax Pharma Reports FY26 Net Loss of ₹4.16 Crore Amid Severe Audit Concerns

Parmax Pharma Ltd has reported a net loss of ₹4.16 crore for the fiscal year ended March 31, 2026, a significant widening from the ₹2.09 crore loss in the previous year. Revenue from operations also saw a substantial decline, falling to ₹12.11 crore from ₹28.20 crore in FY25.

Reader Takeaway: Worsening losses and negative equity, compounded by governance and compliance issues.

What just happened

Parmax Pharma disclosed its financial results for the fiscal year 2026. The company posted a net loss of ₹4.16 crore, compared to a loss of ₹2.09 crore in FY25. Revenue from operations dropped to ₹12.11 crore from ₹28.20 crore.

Why this matters

The financial performance indicates a deteriorating financial health for the company. A widening loss and shrinking revenue are concerning. Furthermore, significant audit observations related to fund diversion and regulatory non-compliance cast a shadow over the company's governance and operational integrity.

The backstory

In the previous fiscal year (FY25), Parmax Pharma had already reported a net loss of ₹2.09 crore. The current results show a worsening trend. The company's total equity has turned negative, standing at ₹-6.15 crore as of March 31, 2026.

What changes now

Investors will be closely watching how the company addresses the critical audit matters raised. These include the misuse of company funds, unauthorized deposit acceptance, and discrepancies in accounting for depreciation and employee benefits. The company's ability to rectify these issues will be crucial for its future prospects.

Risks to watch

Key risks include the impact of the negative equity on future funding, potential regulatory actions arising from the audit findings, and the uncertainty surrounding a ₹3.69 crore insurance claim for a fire incident.

Peer comparison

(No peer comparison data available in the filing.)

Context metrics (time-bound)

• Revenue from Operations (FY26): ₹12.11 crore (down from ₹28.20 crore in FY25)
• Net Loss (FY26): ₹4.16 crore (widened from ₹2.09 crore in FY25)
• Total Equity (as of Mar 31, 2026): ₹-6.15 crore
• Non-current Borrowings (as of Mar 31, 2026): ₹11.52 crore

What to track next

Investors should monitor any management commentary on the audit observations, progress on rectifying governance issues, and any updates on the insurance claim. The company's strategy to improve operational performance and financial health will be critical.